Assessment of Clinical Outcome of Patients With Primary Myelofibrosis Treated ‎With Ruxolitinib in the Real-World Practice

Alaa Fadhil Alwan, Yaseen Muhialdeen Taher and Hayder Adnan Fawzi

Global Journal of Health Science, 2019, vol. 11, issue 6, 106

Abstract: BACKGROUND- Primary myelofibrosis (PMF) is a disease that characterized by bone ‎marrow fibrosis which ‎may ‎result sometime in cytopenias and extramedullary ‎hematopoiesis causing massive ‎splenomegaly. Ruxolitinib (Rux) therapy that targeted ‎Janus Kinase-2 receptor and approved ‎for treatment of primary myelofibrosis. ‎ OBJECTIVE- evaluate the clinical ‎outcome of patients with ‎primary myelofibrosis ‎receiving Ruxolitinib treatment as ‎a compassionate use program ‎and compare this treatment with the best ‎available treatment (BAT).‎ METHODS- ‎This is a retrospective case series conducted at the national ‎center of hematology /‎‎Mustansiriyah University. The enrollment of patients started ‎in May 2014 and ended in May ‎‎2017. There were ‎‎22 patients diagnosed with PMF (7 on ‎the Ruxolitinib arm and 15 on best ‎available treatment arm). The ‎treatment response ‎was evaluated according to consensus criteria ‎of IWG-MRT 2013 in primary ‎‎myelofibrosis. RESULTS- In this study 3 out of 7 patients on Ruxolitinib arm showed reduction in spleen size and reduction in anemia. In addition to ‎that 4 patients ‎showed clinical response specifically in spleen ‎size (with 65% reduction from baseline during the first three months of treatment). CONCLUSION- Rux is effective and safe to treating ‎primary myelofibrosis with ‎symptomatic splenomegaly.

Date: 2019
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://www.ccsenet.org/journal/index.php/gjhs/article/download/0/0/39418/40267 (application/pdf)
http://www.ccsenet.org/journal/index.php/gjhs/article/view/0/39418 (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:ibn:gjhsjl:v:11:y:2019:i:6:p:106

Access Statistics for this article

More articles in Global Journal of Health Science from Canadian Center of Science and Education Contact information at EDIRC.
Bibliographic data for series maintained by Canadian Center of Science and Education ().